TFFP - TFF Pharma inks development pact with Augmenta for COVID-19 therapies

TFF Pharmaceuticals ([[TFFP]] +6.0%) and Augmenta Bioworks have entered into a development and collaboration agreement to develop products incorporating latter’s human-derived monoclonal antibodies ((mAbs)) for potential COVID-19 therapeutics.The products will be developed utilizing TFF Pharma's Thin-Film Freezing technology to manufacture dry powder formulations of specific mAbs for inhalation delivery directly to the lungs of patients.The agreement also includes the development of formulations suitable for parenteral (water-soluble or in suspension) administration.TFF Pharmaceuticals will also have the option to develop two additional Augmenta mAbs for indications other than COVID-19.Both the companies will 50-50 split all costs & expenses and revenues, cash payments and/or future cash payments.

For further details see:

TFF Pharma inks development pact with Augmenta for COVID-19 therapies